China’s quota in the world photovoltaic cell market Broken 80%and for the moment only India seems to have the ability to disturb him in the long term. Its manufacturing capacity is 17 times greater than the rest of the planet togetherwhich has encouraged the Chinese administration to support the manufacture of More than 1,000 GW in N -type cell capacity As the other countries fulfill their net emission commitments.
On the other hand, China is also a world leader in The production of lithium batteries. If we stick to electric cars the country led by Xi Jinping Fabrica 57% of batteries that these vehicles use. Catl and Byd are the largest lithium batteries manufacturers on the planet with A market share in 2023 34% and 16% respectively. Its absolute leadership in these two sectors is the result of a strategy that prioritizes investment in R&D and large -scale production to shoot competitiveness. Now Chinese biotechnological companies plan to apply this successful formula to medicines.
China has the ability to drastically reduce the cost of medical care
“We can reduce the costs of medical care and benefit more people through technological innovation and the improvement of efficiency (…) the recent achievements of China in the field of biotechnology show that it is possible to do it,” says Da Liuthe CR-CP Managing Director Life Science Fund, a risk capital investment group created by the Chinese state and the Thai chain Pokphand Group conglomerate with the purpose of investing in biotechnology companies.
“We can reduce medical care costs and benefit more people through technological innovation and efficiency improvement”
Chinese pharmaceuticals and biotechnology are living a “Deepseek”. This means simply that the medications they develop are every time most demanded by multinational corporations. What the latter pursue is to obtain the necessary licenses to market, produce or distribute the medications developed in China without elaborating them from scratch.
Just three weeks ago the American investment bank Jefferies published a report in which he argues that Chinese companies and assets are extraordinarily competitive thanks to “their efficiency in costs, their small deadlines and the quality of the resulting product.” Interestingly, in seven of the ten main agreements carried out by the global pharmaceutical industry during the first semester of 2025, Chinese licenses were involved, According to the Pharmcube consultant.
The success of the Chinese pharmaceutical industry is supported by a strategy very similar to that which has led this Asian country to lead the markets of solar panels and lithium batteries. However, China does not have it as easy as it seems. And it is that the geopolitical tensions that mainly support the countries led by Donald Trump and Xi Jinping are very difficult for Chinese biotechnological companies their international expansion through mergers with foreign companies. According to Liu What they need to transform into great multinational actors in the pharmaceutical industry is to achieve a dominant position in at least one or two fields of biotechnology.
Image | Edward Jenner
More information | SCMP
GIPHY App Key not set. Please check settings